Partner With Us NRI

Alembic Pharmaceuticals Ltd

Company details

6M Return -23.12%
1Y Return -28.75%
Mkt Cap.(Cr) 10,596.71
Volume 3,735
Div Yield 1.86%
OI Chg %
Volume 3,735

Open Free Demat Account Online with ICICIDIRECT

About The Stock

    Alembic Pharma operates in international generics (US:31% & ex-US: 15% in FY22), domestic branded (36% in FY22) and API (18% in FY22).

    • Domestic business has 1.5% of market share of IPM with three brands in the top 100. Going ahead, emphasis is on specialty segment with 94% of new launches being specialty products
    • The company has invested ~ ₹ 1800 crore in recent years in facilities geared mainly towards US formulations. As of FY22, it has filed 230 ANDA and has 160 approvals with 105 launches in the US


    Alembic reported traction in US, while profitability was affected due to non-recurring expenses at its subsidiary Aleor (now wholly owned)

    • Sales grew 10.6% YoY to ₹ 1415.7 crore, driven by 17.3% YoY growth in US generics to ₹ 557 crore
    • EBITDA was at ₹ 160.1 crore, down 50% YoY with margins at 11.3%. Adjusted EBITDA for Aleor’s impact was ₹ 286 crore with margins at 20%
    • PAT was at ₹ 35.5 crore (down 85.9% YoY). Adjusting for ₹ 145 crore impact of Aleor, adjusted PAT was at ₹ 180.5 crore

Click here for full recommendation

Research view on more stocks

Alembic Pharmaceuticals Ltd.

Q2FY23 Quarterly Result Announced for Alembic Pharmaceuticals Ltd.

Alembic Pharmaceuticals announced Q2FY23 results:

  • Q2FY23 & H1FY23:
    • Net Sales for the quarter were up 14% to Rs 1,475 crore.
    • Net Profit for the quarter at Rs 133 crore.
    • Net sales for H1FY23 at Rs 2,737 crore.
    • Net profit for H1FY23 at Rs 67 crore.

Mr. Pranav Amin, Managing Director, Alembic Pharmaceuticals Limited said "It was a satisfactory quarter led by growth in all the verticals of the company, in particular the API business outperformed with a 23% growth during the quarter"

Result PDF

View Other Company Results


Investment recommendation

Call Date

05 Aug 2022

Entry Price


Target Price



12-18 Month



Operating Profit

Profit after Tax


Reserves and Surplus



Operating Profit

Profit after Tax






Equity Capital: 5,237.54 Cr FV: 2.00

Period MF Net Purchase / (sold) FII Net
LAST 1M 9,798.25 -25,291.97
LAST 3M 27,044.95 -25,544.90
LAST 6M 49,131.67 47,902.81
LAST 12M 178,925.96 -114,950.83

Board Meeting for Today

Feb 01, 2023 l Board Meetings for Today

NSE Board Meetings Forthcomming

Feb 01, 2023 l NSE Board Meetings Forthcomming

Alembic Pharmaceuticals Limited - Loss of Share Certificates

Jan 30, 2023 l NSE Announcement

Date Action Type Ratio
Aug 17, 2022 Dividend 500
Jul 19, 2021 Dividend 700


Stock PE (TTM)


Promoter Holding


Book Value







  • Alembic Pharmaceuticals Ltd., a pharmaceutical company engaged in manufacturing pharmaceutical products, substances, and intermediates, is recognised as a market leader in India for anti-infective drugs in the macrolides segment. The company was incorporated in 1907, with its headquarters in Vadodara. For FY 2021-2022, Alembic Pharmaceuticals Ltd. recorded a total revenue of Rs 5,356.25 crore, down 0.87% from the previous financial year, 2020-2021. On 10 October 2022, the company’s market capitalisation stood at Rs 12,014 crore.

    The company is listed on the Bombay Stock Exchange with the code 533573, and on the National Stock Exchange with the code APLLTD.

    Alembic Pharmaceuticals Ltd. manufactures and markets Indian formulations, international generics, and active pharmaceutical ingredients across the globe. During the quarter that ended in June 2022, the company reported a loss of Rs 65.88 crore after three consecutive quarters of profits.

    The company’s shareholding pattern at the end of the June 2022 quarter represented a promoter stake of 69.61%, a foreign institutional investor stake of 5.94%, a domestic institutional investor stake of 12.15%, and a public stake of 12.3%. The leading promoter was Nirayu Limited having a 35.63% stake. During the same quarter, the company’s mutual fund holdings decreased from 5.18% to 5.01%, and foreign institutional investor holdings also decreased from 6.02% to 5.94%.

    Mr Chirayu Amin is the company’s chairman and CEO. Mr Praniv Amin and Mr Shaunak Amin are the managing directors. The other members of the leadership team include Mr Raj Kumar Baheti, Mr Pranav Parikh, Mr K G Ramanathan, Mr Ashok Barat, Mr Paresh Saraiya, and Dr Archana Hingorani. The company’s auditors include K C Mehta & Co and K S Aiyar & Co. As of 30 June 2022, Alembic Pharmaceuticals Ltd.’s total outstanding shares were 19.66 crores.

    On 10 October 2022, Alembic Pharmaceuticals Ltd.’s share price closed at Rs 610.30 on BSE and at Rs 611.25 on NSE. The company’s 52-week high share price was Rs 864.05, and the 52-week low share price was Rs 577.75.

    As of September 2022, Union Liquid Fund had a 5.23% stake in Alembic Pharmaceuticals Ltd. The other mutual fund holdings include Kotak Small Cap Fund, DSP Midcap Fund, and DSP Healthcare Fund, with a 2.10%, 1.63%, and 1.39% stake, respectively.

    Disclaimer: ICICI Securities Ltd. (I-Sec). Registered office of I-Sec is at ICICI Securities Ltd. - ICICI Venture House, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025, India, Tel No : 022 - 6807 7100. I-Sec is a Member of National Stock Exchange of India Ltd (Member Code :07730), BSE Ltd (Member Code :103) and Member of Multi Commodity Exchange of India Ltd. (Member Code: 56250) and having SEBI registration no. INZ000183631. Name of the Compliance officer (broking): Mr. Anoop Goyal, Contact number: 022-40701000, E-mail address: complianceofficer@icicisecurities.com. Investment in securities market are subject to market risks, read all the related documents carefully before investing. The contents herein above shall not be considered as an invitation or persuasion to trade or invest.  I-Sec and affiliates accept no liabilities for any loss or damage of any kind arising out of any actions taken in reliance thereon. The contents herein above are solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments or any other product. Investors should consult their financial advisers whether the product is suitable for them before taking any decision. The contents herein mentioned are solely for informational and educational purpose

Registered Address

Alembic Road, , Vadodara, Gujarat, 390003

Tel : 91-0265-2280550
Email : apl.investors:alembic.co.in
Website : http://www.alembicpharmaceuticals.com


Link Intime India Pvt Ltd

AGM Date (Month) : Jul
Face Value Equity Shares : 2
Market Lot Equity Shares : 1
BSE Code : 533573
Book Closure Date (Month) : Jul
BSE Group : A
ISIN : INE901L01018

ICICIdirect Alembic Pharmaceuticals Ltd FAQ

You can buy Alembic Pharmaceuticals Ltd shares through a brokerage firm. ICICIdirect is a registered broker through which you can place orders to buy Alembic Pharmaceuticals Ltd Share.
Company share prices and volatile and keep changing according to the market conditions. As of Jan 31, 2023 04:01 PM the closing price of Alembic Pharmaceuticals Ltd was ₹ 539.10.
Market capitalization or market cap is determined by multiplying the current market price of a company’s shares with the total number of shares outstanding. As of Jan 31, 2023 04:01 PM, the market cap of Alembic Pharmaceuticals Ltd stood at ₹ 10,596.71.
The latest PE ratio of Alembic Pharmaceuticals Ltd as of Jan 31, 2023 04:01 PM is 37.87
The latest PB ratio of Alembic Pharmaceuticals Ltd as of Jan 31, 2023 04:01 PM is 0.48
The 52-week high of Alembic Pharmaceuticals Ltd is ₹ 792.30 while the 52-week low is ₹ 532.70
According to analyst recommendations, Alembic Pharmaceuticals Ltd has a “Buy” rating for the long term.

Download Our App

market app
market app